Welcome to SafeSciMET course registration
SafeSciMET in a nutshell
SafeSciMET is a new and unique pan-European safety sciences education and training network, providing a university-accredited medicines safety master’s programme.
Scientists filling entry criteria and successfully completing the full programme, including an integrative MSc thesis, are awarded the Master of Advanced Safety Sciences for Medicines (MAS2M). This is accredited by the University of Constance, Germany. The individual courses of the SafeSciMET programme can also be taken one by one for personal Continuing Professional Development (CPD).
The education and training network is made up of universities, pharmaceutical companies and learned societies, representing the scientific community.
Reasons for establishing it include lack of holistic, integrative and translational approaches in medicines safety education and training in Europe. SafeSciMET aims to solve this shortfall, by contributing to a new “breed” of safety scientists for the pharmaceutical industry, the regulatory authorities, academia, and other in the healthcare sector. The tailor-made safety sciences education and training courses encompass safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on holistic, integrative, translational and 3Rs aspects of drug safety assessment.
Individual safety scientists and professionals, who wish to address specific knowledge gaps, can follow single courses of the SafeSciMET master’s level programme. The modular set-up provides excellent opportunities in building subsets of courses, to be accredited for Continuing Professional Development (CPD) by individual professional bodies and scientific associations. Collaborative work towards a European framework for Continuing Professional Development for those in medicines research, development, processing and usage has started.
All education and training courses and procedures are aligned with the Bologna process for academic collaboration.
SafeSciMET is funded by the Innovative Medicines Initiative Joint Undertaking (IMI JU).